~~<i id='4405B8A78C'><strike id='4405B8A78C'><tt id='4405B8A78C'><pre id='4405B8A78C'></pre></tt></strike></i>~~

Home» focus» entertainment

entertainment

author：leisure time 2025-09-13 15:16:36 Page View：1486

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood
Next article： Dobbs anniversary: the lost opportunity of abortion as health care

explore

Medical records are filled with copy

AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

Humana, CVS hope to turn members into patients at clinics

AdobeBothHumanaandCVSHealthonWednesdaytoutedplanstoaggressivelyscaletheirprimarycareclinicsforsenior

23andMe had bad news about my health. I wish a person had delivered it

ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

The new HIV moral panic

Gilead'sPrEPpillTruvadaJustinSullivan/GettyImagesInMay,justbeforePrideMonth,theCentersforDiseaseCont